X

Trial Profile

Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors: A Phase I, Open-label, Dose-escalation Study

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BPI 9016 (Primary)
Indications Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Betta Pharmaceuticals Co Ltd

Most Recent Events

26 Sep 2018 Results (n=20) were presented at the 19th World Conference on Lung Cancer.
05 Jun 2018 Results (n=20) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
14 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com